Progression-free and overall survival prognostication based on radiographic RECIST response for all patients on BR.36 with evaluable RECIST responses.
DISEASE
RECIST response at 12 weeks less clearly distinguished patients with complete/partial responses compared to patients with stable disease for progression-free (8.31 vs 4.27 months, shown in panel 
